Trial record 2 of 1963 for:    Open Studies | "Hematologic Diseases"

Integrated Whole-Genome Analysis of Hematologic Disorders

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01108159
First received: April 19, 2010
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.


Condition Intervention
Hematologic Diseases
Procedure: Blood Draw
Procedure: Skin Biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression [ Time Frame: sample collection at time of routine visit ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

blood, bone marrow, skin biopsy


Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

participants with hematologic disorders

Criteria

Inclusion Criteria:

  1. 18 years of age or older
  2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
  3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

  1. Less than 18 years of age
  2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108159

Contacts
Contact: Jason D Merker (650) 922-1885 jdmerker@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Jason D Merker    650-922-1885    jdmerker@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: James L Zehnder         
Sub-Investigator: Scott Boyd         
Sub-Investigator: Athena M. Cherry         
Sub-Investigator: Andrew Fire         
Sub-Investigator: Jason Robert Gotlib         
Sub-Investigator: Eleanor L. Marshall         
Sub-Investigator: Jason Merker         
Sub-Investigator: Stephen Tracy Oh         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: James L Zehnder Stanford University
  More Information

No publications provided by Stanford University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01108159     History of Changes
Other Study ID Numbers: HEM0013, 1081737-100-DHAAT, SU-09092009-3820, 16329
Study First Received: April 19, 2010
Last Updated: July 1, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hematologic Diseases

ClinicalTrials.gov processed this record on September 18, 2014